Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris
| Autor: | M.P.M. de Maat, S. van Buuren, C. Kluft, A.E.R. Arnold, Wilson Jh |
|---|---|
| Přispěvatelé: | Gaubius Instituut TNO |
| Jazyk: | angličtina |
| Rok vydání: | 1996 |
| Předmět: |
Male
double blind procedure Fibrinogen Reference Values Platelet fibrin thrombocyte aggregation Volunteer Cross-Over Studies biology Acute-phase protein article clinical trial dna polymorphism Hematology Middle Aged female C-Reactive Protein priority journal Platelet aggregation inhibitor c reactive protein medicine.drug Adult medicine.medical_specialty crossover procedure Ticlopidine thrombocyte count fibrinogen blood level Fibrin Angina Pectoris Double-Blind Method Internal medicine acute phase response fibrinogen metabolism medicine Humans controlled study human normal human Antigens Biology Aged controlled clinical trial business.industry C-reactive protein thrombocyte Endocrinology Case-Control Studies Immunology randomized controlled trial biology.protein business Platelet Aggregation Inhibitors |
| Zdroj: | Fibrinolysis, SUPPL. 1, 10, 12-13 Scopus-Elsevier Thrombosis and Haemostasis, 2, 76, 166-170 |
| Popis: | Elevated plasma fibrinogen levels represent an increased risk for cardiac events. Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases. The mechanism of this decrease has not yet been elucidated and therefore mechanisms that are known to affect fibrinogen levels were studied, viz. the acute phase reaction, total fibrin and fibrinogen degradation (TDP) levels and the fibrinogen G/A4 -gene polymorphism. The fibrinogen lowering effect of ticlopidine was studied in 26 healthy volunteers and in 26 patients with stable angina pectoris in a double blind, randomized cross-over study versus placebo. Functional plasma fibrinogen levels were measured with the Clauss assay and antigen levels with an enzyme immunoassay. C-reactive protein (CRP) and TOP levels were measured with an enzyme immuno assay. In the healthy volunteers the mean (SD) baseline level of functional plasma fibrinogen was 2.35 g/L (SD 0.35) and for fibrinogen antigen this was 2.49 g/L (SD 0.63). The geometrical mean (central 95% range) of CRP as 0.21 mg/L (0.02-2.36) and for TOP this was 0.18 ng/mL (0.03-1.00). After 4 weeks of ticlopidine administration, the functional fibrinogen levels had decreased with 0.20 g/L (9%, p=0.005 using the paired Student t-test) whereas the fibrinogen antigen levels, the CRP and the TOP levels had not significantly changed. In the stable angina pectoris patient the mean (SD) baseline levels of functional plasma fibrinogen were 3.44 g/L (SD 0.61) and of fibrinogen antigen they were 2.60 g/L (SD 0.49). The geometrical mean (central 95% range) of CRP was 1.45 mg/L (0.15-14.44) and for TOP this was 0.28 ng/mL (0.05-1.62). These baseline fibrinogen, CRP and TOP levels were significantly higher than in the volunteer group. After four weeks ticlopidine administration the functional fibrinogen levels had decreased with 0.39 g/L (11%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|